PURPOSE: To evaluate the prognostic value of preoperative plasma osteopontin (OPN) levels in patients with early stage of hepatocellular carcinoma (HCC). METHODS: Preoperative plasma levels of OPN were detected by ELISA in 68 patients with tumor-node metastasis system stage-I of HBV-related HCC, and their association with tumor recurrence or patients' survival was analyzed. RESULTS: The median plasma OPN level of patients was 82.51 ng/ml (25–75% interquartile range, 63.15–110.45 ng/ml). Plasma OPN levels in patients with tumor size C5 cm in diameter were significantly higher than that of patients with tumor size\5 cm in diameter (104.76 vs.75.16 ng/ml, P = 0.003). When the 100 ng/ml was used asa cut-off value to divide the patients into two groups: the higher plasma OPN group and the lower plasma OPN group, the tumor recurrence rate of the higher plasma OPN group was significantly higher than that of the lower plasma OPN group (52.17 vs. 24.44%, P = 0.022). Meanwhile, the recurrence rate of the patients with positive alpha fetoprotein (AFP) (45.5%) was significantly higher than that of those negative AFP patients (12.5%,P = 0.006). A higher plasma OPN level was one leading independent prognostic factor for both overall survival(OS) and relapse-free survival in multivariate Cox models. CONCLUSION: The preoperative plasma OPN level and serum AFP level in patients with early stage of HCC can be used as a prognostic marker for early stage of HCC.
PURPOSE: To evaluate the prognostic value of preoperative plasma osteopontin (OPN) levels in patients with early stage of hepatocellular carcinoma (HCC). METHODS: Preoperative plasma levels of OPN were detected by ELISA in 68 patients with tumor-node metastasis system stage-I of HBV-related HCC, and their association with tumor recurrence or patients' survival was analyzed. RESULTS: The median plasma OPN level of patients was 82.51 ng/ml (25–75% interquartile range, 63.15–110.45 ng/ml). Plasma OPN levels in patients with tumor size C5 cm in diameter were significantly higher than that of patients with tumor size\5 cm in diameter (104.76 vs.75.16 ng/ml, P = 0.003). When the 100 ng/ml was used asa cut-off value to divide the patients into two groups: the higher plasma OPN group and the lower plasma OPN group, the tumor recurrence rate of the higher plasma OPN group was significantly higher than that of the lower plasma OPN group (52.17 vs. 24.44%, P = 0.022). Meanwhile, the recurrence rate of the patients with positive alpha fetoprotein (AFP) (45.5%) was significantly higher than that of those negative AFPpatients (12.5%,P = 0.006). A higher plasma OPN level was one leading independent prognostic factor for both overall survival(OS) and relapse-free survival in multivariate Cox models. CONCLUSION: The preoperative plasma OPN level and serum AFP level in patients with early stage of HCC can be used as a prognostic marker for early stage of HCC.
Authors: Jae-Hoon Kim; Steven J Skates; Toshimitsu Uede; Kwong-kwok Wong; John O Schorge; Colleen M Feltmate; Ross S Berkowitz; Daniel W Cramer; Samuel C Mok Journal: JAMA Date: 2002-04-03 Impact factor: 56.272
Authors: Jean-Nicolas Vauthey; Gregory Y Lauwers; Nestor F Esnaola; Kim-Anh Do; Jacques Belghiti; Nadeem Mirza; Steven A Curley; Lee M Ellis; Jean-Marc Regimbeau; Asif Rashid; Karen R Cleary; David M Nagorney Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: Quynh-Thu Le; Patrick D Sutphin; Soumya Raychaudhuri; Sheue Ching T Yu; David J Terris; Ho Sheng Lin; Bert Lum; Harlan A Pinto; Albert C Koong; Amato J Giaccia Journal: Clin Cancer Res Date: 2003-01 Impact factor: 12.531
Authors: Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun Journal: CA Cancer J Clin Date: 2003 Jan-Feb Impact factor: 508.702
Authors: J G Fox; Y Feng; E J Theve; A R Raczynski; J L A Fiala; A L Doernte; M Williams; J L McFaline; J M Essigmann; D B Schauer; S R Tannenbaum; P C Dedon; S A Weinman; S M Lemon; R C Fry; A B Rogers Journal: Gut Date: 2010-01 Impact factor: 23.059
Authors: A Filia; F Elliott; T Wind; S Field; J Davies; K Kukalizch; J Randerson-Moor; M Harland; D T Bishop; R E Banks; J A Newton-Bishop Journal: Oncol Rep Date: 2013-08-08 Impact factor: 3.906